Cancer-related Fatigue
Conditions
Interventions
Control group:Routine care and symptomatic supportive treatment with both Western and Chinese medicine (pain relief, enteral and parenteral nutrition, use of Chinese herbal decoctions/patented Chinese
Observation group:In addition to the control group, combined treatment with electronic moxibustion (device: Shenzhen Beiqingsong EMI-M, acupoints: Waiguan, Juque, Zhongwan, etc., twice a week, 60 minu
Sponsors
Shenzhen Bao'an District Traditional Chinese Medicine Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Female, pathologically confirmed malignant tumor (refer to CSCO 2020 guidelines); 2) Age 18–60 years; 3) KPS score = 20; 4) Expected survival time > 6 months; 5) Informed and willing to cooperate with treatment; 6) Traditional Chinese medicine diagnosis: deficiency of both Qi and blood (refer to 'Guiding Principles for Clinical Applications of New Chinese Herbal Medicines (Trial)' 2002 edition).
Exclusion criteria
Exclusion criteria: 1. Patients with metastatic cancer; 2. Patients undergoing radiotherapy, chemotherapy, targeted therapy, or immunotherapy; 3. Patients with severe liver or kidney dysfunction, or acute infectious diseases; 4. Patients with serious primary diseases such as cardiovascular, cerebrovascular, or hematopoietic system disorders; 5. Pregnant or breastfeeding women; 6. Individuals with allergies or those allergic to electronic moxibustion treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in total score of the Piper Fatigue Scale-Revised (PFS-R) from baseline (with a significant decrease in total score in the observation group compared to the control group considered as effective).; | — |
Secondary
| Measure | Time frame |
|---|---|
| After 6 weeks of intervention, the change in the total score of the Piper Fatigue Scale-Revised (PFS-R) from baseline in the two groups of patients (with a significantly greater decrease in the total score of the observation group compared to the control group considered effective);Changes in peripheral blood T cell subsets (CD3 T/lymphocytes, CD3 CD4 T/lymphocytes, etc.) and tumor markers (CEA, CA125, CA153) before and after intervention;Incidence of adverse reactions during the intervention; | — |
Countries
China
Contacts
Public ContactXiejiajia Wufanwei
Shenzhen Bao'an District Traditional Chinese Medicine Hospital
Outcome results
None listed